This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
This month features big announcements from Biogen on their acquisition of Reata and their Nrf2 activator for Friedreich’s ataxia and…
Article
2 months ago ●
2 mins read
A pioneering oral OX2R agonist from Takeda for treatment of narcolepsy. TAK-994 is an oral, selective OX2R agonist developed by…
molecule
2 months ago ●
10 mins read
(GLPG1690): The First Clinical Autotaxin (ATX) Inhibitor for IPF Ziretaxestat, an oral autotaxin (ATX) inhibitor originated by Galapagos, once garnered…
molecule
2 months ago ●
9 mins read
Orforglipron: A pioneering oral non-peptide GLP-1 receptor partial agonist for obesity Orforglipron is an oral non-peptide Glucagon-like peptide-1 (GLP-1) receptor…
molecule
2 months ago ●
12 mins read
Targeted Protein Degradation (TPD) allows for elimination, rather than inhibition, of proteins by exploiting cells’ own protein clearance mechanisms. While…
resource
2 months ago ●
16 mins read
A diaziridine-based tumor-activated prodrug for AKR1C3-expressing cancers from a defunct Bay Area biotech. OBI-3424 (formerly TH-3424) is a tumor-activated prodrug…
molecule
2 months ago ●
5 mins read
Load More
